Catalyst Offers Insights on FDA and the Political Landscape During FDA/CMS Summit Panel Discussion
On Dec. 11, Catalyst President Nancy Bradish Myers spoke as [...]
How a Rapid and Well Messaged FDA Offense Is Driving Spectators to Their Feet and Twitter Accounts
The Pink Sheet- “How is FDA doing under Commissioner Scott [...]
RWE at the Tipping Point: From Registries to Artificial Intelligence, RWE is Poised to Accelerate Medical Product Development
By Anne McNickle This is an exciting time for those [...]
The Digital Health Tsunami Is Here. How Is FDA Gearing Up?
Med Device Online – In this “Insider’s View” column, Catalyst [...]
Catalyst to Speak on FDA & Innovation, Market Trends Affecting the Future of Health Care, and RWE in Drug Development
Catalyst Healthcare Consulting will be speaking at a number of [...]
Artificial Intelligence (AI): Coming to a Policymaker Near You
By Nancy Bradish Myers It’s as if Artificial Intelligence just [...]
Digital Health: New Law Encourages Telehealth Services For Medicare Patients
By Nancy Bradish Myers As Congress moved to keep the [...]
Shutdown Winds Down: Short ‘Lapse Period’ Likely Means Few Disruptions At US FDA
The Pink Sheet- This article looks at the impact of [...]
How a government shutdown could affect drug safety, flu response, and more
In this article, Catalyst’s Jill Hartzler Warner provides context for [...]
New FDA Leadership Changes Priorities But Doesn’t Change Administration Regulations, Panel Discussion Says
Biotech Investing News— Biotech Investing News reporters this week covered [...]